Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 70/100

RAD secures Share Facility Agreement of up to A$12.5m

Tuesday, February 6, 2024 1 min read
Key Takeaway: Radiopharm Theranostics (RADX) has successfully secured a Share Facility Agreement worth up to A$12.5 million. This funding is expected to bolster the company's financial position and support its ongoing clinical programs. The announcement reflects RAD's proactive approach to capital raising in the biopharma sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • RAD has secured a significant share facility agreement.
  • The agreement amounts to up to A$12.5 million.
  • This funding can support ongoing clinical studies.

Full Press Release Details

• Announcements
• Price Sensitive
• February 6, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• October 18, 2022
• Announcements
• May 19, 2025
• Announcements
• March 12, 2024
• Annual Reports
• September 28, 2023

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the amount of the Share Facility Agreement?

The Share Facility Agreement is worth up to A$12.5 million.

What will the funding support?

The funding will support ongoing clinical studies at Radiopharm Theranostics.

Who is the company behind the agreement?

The agreement is secured by Radiopharm Theranostics, ticker RADX.

When was the announcement made?

The announcement was made on February 6, 2024.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics clinical studies funding capital raising
Last updated: Feb 6, 2024